Bioreactors are essential tools in biotechnology, enabling controlled environments for cell culture, fermentation, and metabolite production. Their role is crucial in biopharmaceutical manufacturing, regenerative medicine, and large-scale cell expansion. As bioprocessing demands grow, bioreactor scale-up becomes a key challenge, ensuring that laboratory-developed processes translate effectively into industrial-scale production.

Cell and Gene Therapies (CGT) represent a groundbreaking advancement in modern medicine, offering curative potential for genetic disorders, cancer, and degenerative diseases. These therapies utilize engineered cells or genetic modifications to treat or replace damaged tissues and defective genes. All approaches demand highly controlled manufacturing processes to ensure safety, efficacy, and scalability.

Sustainability has long been considered a "nice-to-have" in biotech and pharma - but this is changing fast. With the advent of binding regulations like the European Green Deal and its global counterparts, sustainability is moving from corporate responsibility to legal obligation.